HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 4-10

  Arteaga, Carlos L ^a   Moulder, Stacy L ^a   Yakes, F Michael ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0036312252     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70121-8     Document Type: Conference Paper

References (44)

1. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: Its role in cell growth and disease
2. The protein tyrosine kinase family of the human genome
3. Oncogene kinase signalling
4. Cell signaling by receptor tyrosine kinases
5. Dimerization of cell surface receptors in signal transduction
6. Cancer and genomics
7. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
8. The ErbB signaling network: Receptor heterodimerization in development and cancer
9. ErbB-2 the preferred heterodimeization partner of all ErbB receptors is a mediator of lateral signaling
10. Untangling the ErbB signalling network
11. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
12. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
13. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
14. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
15. Coexpression of erbB 2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
16. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB 4
17. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
18. Epidermal growth factor-related peptides and their receptors in human malignancies
19. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
20. Oncogenic potential of erbB-2 in human mammary epithelial cells
21. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
22. Humanization of an anti-p185HER2 antibody for human cancer therapy
23. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
24. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
25. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation
26. EGF-stimulated tyrosine phosphorylation of p185neu: A potential model for receptor interactions
27. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
28. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
29. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
30. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice
31. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
32. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
33. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation
34. ZD1839 ('Iressa') as an anticancer agent
35. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
36. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
37. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers
38. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
39. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
40. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
41. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
42. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
43. Optimal two-stage designs for phase II clinical trials
44. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways